Ocular Therapeutix: Pay

Ocular Therapeutix paid its 5 named executives $50.0M in total in FY2025 (Dec). CEO Pravin U. Dugel, M.D. was paid $35.9M of that.

Pay$100 in the stock at the end of FY23 → $272
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Pravin U. Dugel, M.D.Executive Chair, President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
2 years
Nadia Waheed, M.D.Chief Medical Officer
FY2025 (Dec)
1 year
Donald NotmanChief Operating Officer and Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Sanjay Nayak, M.B.B.S., Ph.D.Chief Strategy Officer
FY2025 (Dec)
1 year
Steve MeyersChief Commercial Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 5 peers with pay on file was $7.8M. The CEO of Ocular Therapeutix was paid $35.9M, 361% above the median.

  1. 1Ocular Therapeutix
  2. 2ImmunityBio
  3. 3Travere Therapeutics
  4. 4Ardelyx
  5. 5Tarsus Pharmaceuticals
  6. 6Agios Pharmaceuticals
  7. 7Ani PharmaceuticalsNot disclosed
  8. 8Apellis Pharmaceuticals, Inc.Not disclosed
  9. 9Aura Biosciences, Inc.Not disclosed
  10. 10Day One Biopharmaceuticals, Inc.Not disclosed
  11. 11Esperion Therapeutics, Inc.Not disclosed
  12. 12Evolus, Inc.Not disclosed
  13. 13EyePoint, Inc.Not disclosed
  14. 14GeronNot disclosed
  15. 15HarrowNot disclosed
  16. 16Ligand PharmaceuticalsNot disclosed
  17. 17Phathom Pharmaceuticals, Inc.Not disclosed
  18. 18SpringWorks Therapeutics, Inc.Not disclosed
  19. 19VericelNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.